(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 March 2012 (15.03.2012)

PCT

(10) International Publication Number
WO 2012/031603 A2

(51) International Patent Classification:
A61K 9/72 (2006.01) *A61P 35/00* (2006.01)
A61K 31/454 (2006.01) *A61P 11/00* (2006.01)

(21) International Application Number:
PCT/DK2011/050338

(22) International Filing Date:
9 September 2011 (09.09.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2010 00807 9 September 2010 (09.09.2010) DK

(71) Applicants *(for all designated States except US)*: **DANISH MEDICAL CONSULTS APS** [DK/DK]; c/o Lars Heslet, Parkovsvej 20, DK-2820 Gentofte (DK). **BPBD CONSULT APS** [DK/DK]; Egernvej 69, DK-2000 Frederiksberg (DK).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **HESLET, Lars** [DK/DK]; Parkovsvej 20, DK-2820 Gentofte (DK). **FIALA, Kaare** [DK/DK]; Egernvej 69, DK-2000 Frederiksberg (DK).

(74) Agent: **HØIBERG A/S**; St. Kongensgade 59 A, DK-1264 Copenhagen K (DK).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: AIRWAY ADMINISTRATION OF ANGIOGENESIS INHIBITORS




Fig. 1

(57) **Abstract**: The present invention provides methods for the local pulmonary treatment of lung metastases and/or primary lung cancer, such as squamous lung cancer and/or small cell lung cancer, using local deposition of one or more agents capable of inhibiting angiogenesis and/or an agent that acts as an active anti-cancer agent and/or an active anti-metastatic agent. The agent capable of inhibiting angiogenesis and/or which acts as an active anti-cancer agent and/or an active anti-metastatic agent is administered to a patient with cancer as a treatment of said metastasis and/or cancer or to extend the lifespan for said cancer patient with reduced systemic side- effects compared to other treatment forms. The agent capable of inhibiting angiogenesis and/or which acts as an active anti-cancer agent and/or an active anti- metastatic agent is administered intratracheal, intrabronchial, intraalveolar or broncioalveolar. Administration for example via inhalation of an aerosol or as a dry powder and/or administered as a bronchoalveolar lavage (BAL) an effective amount of the agent.

WO 2012/031603 A2